Nizatidine

Evidence Level: L5

Predicted Indications: 3

Nizatidine

Pharmacist Assessment Report

Nizatidine: Duodenal obstruction

One-Sentence Summary

Nizatidine is an H2-receptor antagonist originally used for gastric ulcer, duodenal ulcer, peptic ulcer disease and gastro-oesophageal reflux disease. The TxGNN model predicts it may be effective for duodenal obstruction. No clinical trials are registered in the data compiled for this report, but 20 publications (including several randomised, placebo-controlled trials) support the indication.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Duodenal obstruction
TxGNN Prediction Score	0.9986
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, nizatidine is an H2-receptor antagonist. It blocks histamine-driven gastric acid secretion and reduces basal, nocturnal and stimulated acid output. Acid suppression is the core mechanism behind ulcer healing.

The predicted indication overlaps almost completely with nizatidine’s established uses (gastric ulcer, duodenal ulcer, peptic ulcer disease). The prediction therefore reflects consistency with existing knowledge rather than a new therapeutic direction. The literature includes randomised, placebo-controlled, multicentre trials in active duodenal ulcer and benign gastric ulcer, as well as maintenance-therapy studies.

Other Predicted Indications (for context)

The model also produced lower-ranked predictions. Their support is much weaker:

Predicted Indication	Score	Evidence Level	Assessment
Gastroduodenitis	0.9958	L3	Studies on NSAID-induced gastroduodenal lesions; study designs unclear; Research Question

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Selected publications for active peptic ulcer disease (priority to randomised trials):

PMID	Year	Type	Journal	Key Findings
1526089	1992	RCT	Clin Pharmacol Ther	Eight-week, multicentre, double-blind comparison of nizatidine 150 mg twice daily and 300 mg at bedtime versus placebo in healing active benign gastric ulcer
2570656	1989	RCT	Clin Pharmacol Ther	Two-phase, placebo-controlled trial of nizatidine 150 mg twice daily for duodenal ulcer healing and recurrence
7960687	1994	RCT	Isr J Med Sci	Nizatidine 300 mg nightly versus placebo for 4 weeks in 55 patients with active duodenal ulcer; healing and mucosal inflammatory mediators assessed
2892259	1987	RCT	Scand J Gastroenterol Suppl	One-year maintenance in 513 patients with healed duodenal ulcer; 12-month recurrence 34% with nizatidine versus 64% with placebo
7863254	1994	Open clinical study	Scand J Gastroenterol Suppl	Maintenance nizatidine in healed duodenal ulcer, with quality-of-life assessment
2905640	1988	Review	Drugs	Pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease
2184124	1990	Review	Gastroenterol Clin North Am	Overview of medical therapy of peptic ulcer disease; nizatidine is safe and effective but has no new properties of clinical importance
2892253	1987	Safety summary	Scand J Gastroenterol Suppl	Safety assessment in about 3,800 nizatidine-treated individuals in US and European trials
1355465	1992	Review	Gastroenterol Clin North Am	Control of gastric acid secretion by H2-receptor antagonists and H+/K+-ATPase inhibitors
26883979	2016	Preclinical (rat)	Life Sci	Gastroprotective effects of several H2 antagonists on ibuprofen-induced gastric ulcer

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 14306Y	Tazac	Capsule 150 mg (oral)	Not recorded in the data compiled for this report

Safety Considerations

Contraindication signals from the knowledge graph (not label text): liver disease, gallbladder disease, impaired renal function, and gastric cancer/neoplasm (including diffuse gastric adenocarcinoma and linitis plastica). These should be checked against the TGA Product Information.
Drug interactions (100 interactions recorded; examples shown):
- Major: atazanavir, dasatinib
- Moderate: acalabrutinib, bosutinib, brigatinib, cefditoren, cefpodoxime, cefuroxime, ceritinib, chlorpropamide, dabrafenib, dacomitinib
- Minor: ketorolac, ibuprofen, diclofenac, alendronic acid, axitinib, cyanocobalamin, magnesium oxide, oxaprozin
Many of the major and moderate interactions probably reflect reduced absorption of drugs that need an acidic gastric environment (for example some kinase inhibitors, atazanavir and some cephalosporins). This is an inference, not stated in the data.
A published safety review reports that long-term low-dose H2-antagonist maintenance appears safe over several years (PMID 1679672).

Warnings and contraindications from the approved label were not available. Please refer to the TGA-approved Product Information (PI) for complete safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The evidence is literature-based only; no registered trials were supplied, and most of the studies date from the 1980s and 1990s. The other predictions are indirect or unsupported and should be held.

To proceed, the following is needed:

The TGA-approved Product Information for Tazac, including approved indications, warnings and contraindications (the label review was a blocking data gap)
Mechanism of action data from DrugBank
Confirmation of the ARTG-approved indications against the predicted indication
Comparison with current guidelines, as PPIs are generally preferred for many acid-related conditions
A review of the interaction list, particularly for drugs that need gastric acid for absorption
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.